Health Press Release – Newsletter for February 19, 2011

Medivir – The Phase 3 Program for TMC435 in Treatment-Naive Patients and Patients who Have Relapsed After Prior Interferon-Based Treatment has Now Started

HUDDINGE, Sweden, February 18, 2011 – Medivir AB (OMX: MVIR), the emerging research-based specialty
pharmaceutical company focused on infectious diseases, notes that its
development partner, Tibotec Pharmaceuticals, announced today that the global
phase 3 studies with TMC435 in treatment-naive patients and patients who have
relapsed after prior SOC treatment have started.

Phase 3 Program in …. Source  : Gaea News Network.